Green Tea in Breast Cancer Patients
关键词
抽象
日期
| 最后验证: | 02/28/2018 |
| 首次提交: | 07/28/2009 |
| 提交的预估入学人数: | 07/29/2009 |
| 首次发布: | 07/30/2009 |
| 上次提交的更新: | 03/27/2018 |
| 最近更新发布: | 03/29/2018 |
| 实际学习开始日期: | 05/06/2008 |
| 预计主要完成日期: | 12/13/2010 |
| 预计完成日期: | 06/05/2016 |
状况或疾病
干预/治疗
Dietary Supplement: tea capsules
相
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Active Comparator: tea capsules 3 tea capsules daily for 3 weeks | Dietary Supplement: tea capsules 3 tea capsules daily for 3 weeks |
| No Intervention: Control No tea capsules |
资格标准
| 有资格学习的年龄 | 18 Years 至 18 Years |
| 有资格学习的性别 | Female |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: - Postmenopausal (at least 2 years since last menstrual period) or age 55 or older if prior hysterectomy - Non-current (not with past 6 months) user of menopausal hormones - Mammographic abnormality consistent with any type of incident breast cancer necessitating a diagnostic biopsy (BIRAD IV(b), (c) or V) will be sufficient to draw baseline LFT and complete screening questionnaire. Unless the biopsy confirms incident breast cancer, such subjects will not be included in further research interventions and they will not serve as EGCG treated or control subjects. - Diagnosed with incident breast cancer on the diagnostic biopsy is required for inclusion in the EGCG or control treatment groups. - Non-green tea drinker (less than monthly) - this criteria does not apply to black tea or herbal tea - Provided written informed consent Exclusion Criteria: - Green tea drinker (once per month or more) - History of breast cancer or other cancer including a prior diagnosis of any type of incident breast cancer. - Known allergy to tea - Abnormal liver enzymes (plus or minus 10% of the normal ranges). |
结果
主要结果指标
1. level of reduction in proliferation or increase in apoptosis in association with short-term EGCG [At surgery]
